Literature DB >> 20940147

A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human disease.

David A McDonald1, Robert Shenkar, Changbin Shi, Rebecca A Stockton, Amy L Akers, Melanie H Kucherlapati, Raju Kucherlapati, James Brainer, Mark H Ginsberg, Issam A Awad, Douglas A Marchuk.   

Abstract

Cerebral cavernous malformations (CCMs) are vascular lesions of the central nervous system appearing as multicavernous, blood-filled capillaries, leading to headache, seizure and hemorrhagic stroke. CCM occurs either sporadically or as an autosomal dominant disorder caused by germline mutation of one of the three genes: CCM1/KRIT1, CCM2/MGC4607 and CCM3/PDCD10. Surgically resected human CCM lesions have provided molecular and immunohistochemical evidence for a two-hit (germline plus somatic) mutation mechanism. In contrast to the equivalent human genotype, mice heterozygous for a Ccm1- or Ccm2-null allele do not develop CCM lesions. Based on the two-hit hypothesis, we attempted to improve the penetrance of the model by crossing Ccm1 and Ccm2 heterozygotes into a mismatch repair-deficient Msh2(-/-) background. Ccm1(+/-)Msh2(-/-) mice exhibit CCM lesions with high penetrance as shown by magnetic resonance imaging and histology. Significantly, the CCM lesions range in size from early-stage, isolated caverns to large, multicavernous lesions. A subset of endothelial cells within the CCM lesions revealed somatic loss of CCM protein staining, supporting the two-hit mutation mechanism. The late-stage CCM lesions displayed many of the characteristics of human CCM lesions, including hemosiderin deposits, immune cell infiltration, increased endothelial cell proliferation and increased Rho-kinase activity. Some of these characteristics were also seen, but to a lesser extent, in early-stage lesions. Tight junctions were maintained between CCM lesion endothelial cells, but gaps were evident between endothelial cells and basement membrane was defective. In contrast, the Ccm2(+/-)Msh2(-/-) mice lacked cerebrovascular lesions. The CCM1 mouse model provides an in vivo tool to investigate CCM pathogenesis and new therapies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20940147      PMCID: PMC3005897          DOI: 10.1093/hmg/ddq433

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  48 in total

1.  Ultrastructural pathological features of cerebrovascular malformations: a preliminary report.

Authors:  J H Wong; I A Awad; J H Kim
Journal:  Neurosurgery       Date:  2000-06       Impact factor: 4.654

2.  Mutations in the gene encoding KRIT1, a Krev-1/rap1a binding protein, cause cerebral cavernous malformations (CCM1).

Authors:  T Sahoo; E W Johnson; J W Thomas; P M Kuehl; T L Jones; C G Dokken; J W Touchman; C J Gallione; S Q Lee-Lin; B Kosofsky; J H Kurth; D N Louis; G Mettler; L Morrison; A Gil-Nagel; S S Rich; J M Zabramski; M S Boguski; E D Green; D A Marchuk
Journal:  Hum Mol Genet       Date:  1999-11       Impact factor: 6.150

3.  Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas.

Authors:  S Laberge-le Couteulx; H H Jung; P Labauge; J P Houtteville; C Lescoat; M Cecillon; E Marechal; A Joutel; J F Bach; E Tournier-Lasserve
Journal:  Nat Genet       Date:  1999-10       Impact factor: 38.330

4.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.

Authors:  L A Donehower; M Harvey; B L Slagle; M J McArthur; C A Montgomery; J S Butel; A Bradley
Journal:  Nature       Date:  1992-03-19       Impact factor: 49.962

5.  MSH2 deficiency contributes to accelerated APC-mediated intestinal tumorigenesis.

Authors:  A H Reitmair; J C Cai; M Bjerknes; M Redston; H Cheng; M T Pind; K Hay; A Mitri; B V Bapat; T W Mak; S Gallinger
Journal:  Cancer Res       Date:  1996-07-01       Impact factor: 12.701

Review 6.  Mismatch repair in replication fidelity, genetic recombination, and cancer biology.

Authors:  P Modrich; R Lahue
Journal:  Annu Rev Biochem       Date:  1996       Impact factor: 23.643

7.  An analysis of the natural history of cavernous angiomas.

Authors:  O Del Curling; D L Kelly; A D Elster; T E Craven
Journal:  J Neurosurg       Date:  1991-11       Impact factor: 5.115

8.  Tumors of DNA mismatch repair-deficient hosts exhibit dramatic increases in genomic instability.

Authors:  A Baross-Francis; S E Andrew; J E Penney; F R Jirik
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

9.  Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer.

Authors:  N de Wind; M Dekker; A Berns; M Radman; H te Riele
Journal:  Cell       Date:  1995-07-28       Impact factor: 41.582

10.  Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations.

Authors:  F Bergametti; C Denier; P Labauge; M Arnoult; S Boetto; M Clanet; P Coubes; B Echenne; R Ibrahim; B Irthum; G Jacquet; M Lonjon; J J Moreau; J P Neau; F Parker; M Tremoulet; E Tournier-Lasserve
Journal:  Am J Hum Genet       Date:  2004-11-12       Impact factor: 11.025

View more
  63 in total

Review 1.  Recent advances in vascular development.

Authors:  Courtney K Domigan; M Luisa Iruela-Arispe
Journal:  Curr Opin Hematol       Date:  2012-05       Impact factor: 3.284

2.  Mutations in 2 distinct genetic pathways result in cerebral cavernous malformations in mice.

Authors:  Aubrey C Chan; Stavros G Drakos; Oscar E Ruiz; Alexandra C H Smith; Christopher C Gibson; Jing Ling; Samuel F Passi; Amber N Stratman; Anastasia Sacharidou; M Patricia Revelo; Allie H Grossmann; Nikolaos A Diakos; George E Davis; Mark M Metzstein; Kevin J Whitehead; Dean Y Li
Journal:  J Clin Invest       Date:  2011-04-01       Impact factor: 14.808

Review 3.  Cavernous angiomas: deconstructing a neurosurgical disease.

Authors:  Issam A Awad; Sean P Polster
Journal:  J Neurosurg       Date:  2019-07-01       Impact factor: 5.115

Review 4.  Genetics of cerebral cavernous malformations: current status and future prospects.

Authors:  H Choquet; L Pawlikowska; M T Lawton; H Kim
Journal:  J Neurosurg Sci       Date:  2015-04-22       Impact factor: 2.279

Review 5.  The pathobiology of vascular malformations: insights from human and model organism genetics.

Authors:  Sarah E Wetzel-Strong; Matthew R Detter; Douglas A Marchuk
Journal:  J Pathol       Date:  2016-12-04       Impact factor: 7.996

6.  PDCD10 (CCM3) regulates brain endothelial barrier integrity in cerebral cavernous malformation type 3: role of CCM3-ERK1/2-cortactin cross-talk.

Authors:  Svetlana M Stamatovic; Nikola Sladojevic; Richard F Keep; Anuska V Andjelkovic
Journal:  Acta Neuropathol       Date:  2015-09-18       Impact factor: 17.088

Review 7.  Signaling pathways and the cerebral cavernous malformations proteins: lessons from structural biology.

Authors:  Oriana S Fisher; Titus J Boggon
Journal:  Cell Mol Life Sci       Date:  2013-11-29       Impact factor: 9.261

8.  Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation.

Authors:  Christopher C Gibson; Weiquan Zhu; Chadwick T Davis; Jay A Bowman-Kirigin; Aubrey C Chan; Jing Ling; Ashley E Walker; Luca Goitre; Simona Delle Monache; Saverio Francesco Retta; Yan-Ting E Shiu; Allie H Grossmann; Kirk R Thomas; Anthony J Donato; Lisa A Lesniewski; Kevin J Whitehead; Dean Y Li
Journal:  Circulation       Date:  2014-12-08       Impact factor: 29.690

9.  Two-hit mechanism in cerebral cavernous malformation? A case of monozygotic twins with a CCM1/KRIT1 germline mutation.

Authors:  Philipp Dammann; Ute Hehr; Sabine Weidensee; Yuan Zhu; Rüdiger Gerlach; Ulrich Sure
Journal:  Neurosurg Rev       Date:  2013-04-13       Impact factor: 3.042

10.  Two Novel CCM2 Heterozygous Mutations Associated with Cerebral Cavernous Malformation in a Chinese Family.

Authors:  Qin Du; Ziyan Shi; Hongxi Chen; Ying Zhang; Jiancheng Wang; Hongyu Zhou
Journal:  J Mol Neurosci       Date:  2019-01-30       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.